5-alpha-reductase inhibitor

Revision as of 19:56, 27 September 2011 by WikiBot (talk | contribs) (Protected "5-alpha-reductase inhibitor": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

WikiDoc Resources for 5-alpha-reductase inhibitor

Articles

Most recent articles on 5-alpha-reductase inhibitor

Most cited articles on 5-alpha-reductase inhibitor

Review articles on 5-alpha-reductase inhibitor

Articles on 5-alpha-reductase inhibitor in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on 5-alpha-reductase inhibitor

Images of 5-alpha-reductase inhibitor

Photos of 5-alpha-reductase inhibitor

Podcasts & MP3s on 5-alpha-reductase inhibitor

Videos on 5-alpha-reductase inhibitor

Evidence Based Medicine

Cochrane Collaboration on 5-alpha-reductase inhibitor

Bandolier on 5-alpha-reductase inhibitor

TRIP on 5-alpha-reductase inhibitor

Clinical Trials

Ongoing Trials on 5-alpha-reductase inhibitor at Clinical Trials.gov

Trial results on 5-alpha-reductase inhibitor

Clinical Trials on 5-alpha-reductase inhibitor at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on 5-alpha-reductase inhibitor

NICE Guidance on 5-alpha-reductase inhibitor

NHS PRODIGY Guidance

FDA on 5-alpha-reductase inhibitor

CDC on 5-alpha-reductase inhibitor

Books

Books on 5-alpha-reductase inhibitor

News

5-alpha-reductase inhibitor in the news

Be alerted to news on 5-alpha-reductase inhibitor

News trends on 5-alpha-reductase inhibitor

Commentary

Blogs on 5-alpha-reductase inhibitor

Definitions

Definitions of 5-alpha-reductase inhibitor

Patient Resources / Community

Patient resources on 5-alpha-reductase inhibitor

Discussion groups on 5-alpha-reductase inhibitor

Patient Handouts on 5-alpha-reductase inhibitor

Directions to Hospitals Treating 5-alpha-reductase inhibitor

Risk calculators and risk factors for 5-alpha-reductase inhibitor

Healthcare Provider Resources

Symptoms of 5-alpha-reductase inhibitor

Causes & Risk Factors for 5-alpha-reductase inhibitor

Diagnostic studies for 5-alpha-reductase inhibitor

Treatment of 5-alpha-reductase inhibitor

Continuing Medical Education (CME)

CME Programs on 5-alpha-reductase inhibitor

International

5-alpha-reductase inhibitor en Espanol

5-alpha-reductase inhibitor en Francais

Business

5-alpha-reductase inhibitor in the Marketplace

Patents on 5-alpha-reductase inhibitor

Experimental / Informatics

List of terms related to 5-alpha-reductase inhibitor

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

5α-reductase inhibitors (or 5-alpha-reductase inhibitors) are a group of drugs with antiandrogenic activity, used in the treatment of benign prostatic hyperplasia and androgenic (or androgenetic) alopecia. These drugs decrease the levels of available 5α-reductase prior to testosterone binding with the enzyme, thus reducing levels of dihydrotestosterone that derives from such a bond.

Clinical use

Indications

5α-reductase inhibitors are clinically used in the treatment of conditions which are exacerbated by dihydrotestosterone. Specifically, these indications may include: (Rossi, 2004)

Adverse drug reactions

Adverse drug reactions (ADRs) experienced with 5α-reductase inhibitors are generally dose-dependent. Common ADRs include impotence, decreased libido, decreased ejaculate volume. Rare ADRs include: breast tenderness and enlargement, and allergic reaction. (Rossi, 2004)

Pharmacology

The enzyme 5α-reductase is involved in the conversion of testosterone to the active form dihydrotestosterone by reducing the Δ4,5 double-bond. In benign prostatic hyperplasia, dihydrotestosterone acts as a potent cellular androgen and promotes prostate growth - inhibiting the enzyme reduces the excessive prostate growth. In alopecia, pattern-baldness is one of the effects of androgenic receptor activation. Reducing the levels of dihydrotestosterone thus reduces alopecia.

Examples

References

Template:SIB


Template:WikiDoc Sources